Novel anti-cancer agent shows minimal side effects with preliminary evidence of tumor shrinkage

Research results presented at International Conference sponsored jointly by AACR, NCI and EORTC

Washington, DC, November 16, 1999 --- Researchers presented data here today from an ongoing Phase I clinical trial showing that a novel anti-cancer agent, called CCI-779, is well-tolerated and may have antitumor activity. CCI-779 is a derivative of rapamycin, an immunosuppressive agent. Results were presented at the International Conference on Molecular Cancer Therapeutics - Discovery, Development, and Clinical Validation, sponsored by the American Association of Cancer Research (AACR), the National Cancer Institute (NCI) and the European Organization for Research and Treatment of Cancer (EORTC).

"By interfering with key proteins that regulate cell growth, CCI-779 may stop the progression of tumors. This is a unique mechanism of action for an anti-cancer agent," explained Eric Raymond, M.D., senior investigator and associate professor of oncology at the Institut Gustave Roussy in Villejuif, France. "If these preliminary results are confirmed in future observations, this may represent a new and safer treatment for cancer patients."

The results were presented by Jerome Alexandre, a physician-in-training and researcher with Dr. Raymond, who received an AACR Young Investigator Scholar Award, bestowed on predoctoral students, postdoctoral fellows, and physicians-in-training for outstanding abstracts. The study is being conducted in collaboration with Axel Hanauske, M.D., Ph.D. from the Oncology Institute in Munich, Germany, and the sponsor Wyeth-Ayerst Research in Radnor, Pennsylvania /Genetics Institute in Munich, Germany.

Twelve patients received CCI-779 in this ongoing Phase I study. Three patients with renal cell cancer experienced tumor regression after other treatments had failed. At the doses used so far, the main adverse effects were mild skin reactions and inflammation of the mucous membranes, which occurred at all dose levels

Contact: Peter Vigliarolo
Cooney Waters Group, Inc.

Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:

(Date:5/14/2019)... ... 14, 2019 , ... IMMUNE 3D®, a privately held biotechnology ... of autoimmunity, fibrosis and skin immunology. In addition, the company will leverage its ... efforts. , IMMUNE 3D®’s proprietary platform aims to study factors that affect ...
(Date:5/8/2019)... ... May 08, 2019 , ... RG+A, Inc., ... Carol S. Mann has agreed to serve as Chief Executive Officer and pharmaceutical ... Officer, effective immediately. They will join Chairman and Founder Roger Green to create ...
(Date:5/7/2019)... ... May 07, 2019 , ... ... Beach Convention and Entertainment Center from May 15- 17. At booth #226, AMGtime ... These include flexible software, biometric hardware, mobile apps, specialized industry solutions, advanced add-on ...
Breaking Biology News(10 mins):
(Date:5/2/2019)... ... May 02, 2019 , ... Boston Robotic Hair ... area. Gone are the days of painful hair transplant procedures. Boston Robotic Hair ... is the only robotic intelligent solution to offer a minimally invasive procedure. With ...
(Date:4/25/2019)... , ... April 24, 2019 , ... ... Agents for sales and service organizations, today announced global availability of Inference ... providers and enterprises of all sizes to harness the power of Google’s ...
(Date:4/16/2019)... Md. (PRWEB) , ... April 16, 2019 , ... ... honor Blue Sources and their project partner, the U.S. Army Center for Environmental ... of Aquatic Biomonitor Through Combined In-Licensing/Out-Licensing.” , Blue Sources, a veteran-owned company located ...
(Date:4/15/2019)... ... 2019 , ... Sirrus, Inc., a developer of novel electron-deficient ... to increase production of methylene malonate monomers and oligomers. , The expanded bench ... production facility, which is scheduled to break ground in 2019. “The expanded facility ...
Breaking Biology Technology:
Cached News: